Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases

JAMA. 2021 Dec 21;326(23):2370-2372. doi: 10.1001/jama.2021.21315.

Authors

Zachary S Wallace^{1

2}, Jeffrey A Sparks^{2

3}

Affiliations

¹ Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 34932096
DOI: 10.1001/jama.2021.21315

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Drug Monitoring*
Gastrointestinal Agents*
Infliximab

Substances

Gastrointestinal Agents
Infliximab

Grants and funding